IndustryCompany release

Natera Lifts 2026 Outlook as Q3 Revenue Climbs 34% on Strong MRD Demand

🇺🇸 Natera, Inc. (NTRA) · Thu 05 Nov 2026

The US genetic testing company reported third-quarter revenue of $794M and a surge in clinical MRD oncology volumes, and raised its full-year revenue guidance.

Natera reported third-quarter 2026 revenue of $794M, compared with $592M in the same period a year earlier. The company said it processed more than 1.09M tests in the quarter.

Clinical minimal residual disease (MRD) oncology testing was a standout. Natera handled about 316K clinical MRD tests, covering Signatera and Latitude, an increase of more than 56%. Gross margin was about 65%.

On the back of the results, Natera raised its 2026 revenue outlook by $140M at the midpoint. It also projected annual revenue of $6B in 2029.

The earnings presentation, dated 5 November 2026, pointed to strength in bladder cancer testing following an FDA approval and inclusion in NCCN guidelines. The summary available does not specify the product or indication covered by the approval, and no further detail on the guideline recommendation was provided.

What it means for your team

  • Guideline inclusion and regulatory approval are cited as drivers of MRD test uptake, a link market-access teams may wish to track for other oncology diagnostics.
  • Rising clinical MRD volumes suggest growing routine use of such tests, which may increase attention on test quality, laboratory performance and result interpretation.
  • The company's 2029 revenue projection is a forward-looking statement and not a regulatory or reimbursement commitment.

Company's press release (SEC filing): Natera, Inc. ↗

Article written by VigiEye from the official source (Natera, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →